Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

The Profiteer Free

10/02/06 1:27 PM

Post #3

NO posts???? R U guys looking at this??

furgeson

09/28/06 9:51 AM

Post #2

It there a buyout on the table at MYOG ??

Hanahoe_PC Free

07/26/06 11:01 PM

Post #1

Stock has strong Institutional support and has shown strong relative strength in a period when Biotechs have been hammered.

Myogen (MYOG)

Followers	0	Posters	3
Posts (Today)	0	Posts (Total)	3
Created	07/26/06	Type	Free
Moderators

Myogen is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders. Myogen currently has two product candidates in late-stage clinical development: ambrisentan for the treatment of patients with pulmonary arterial hypertension and darusentan for the treatment of patients with resistant hypertension. Myogen and GlaxoSmithKline have entered into a global PAH collaboration in which Myogen has distribution and marketing rights to GlaxoSmithKline's Flolan (epoprostenol sodium) in the United States for the treatment of PAH and GlaxoSmithKline has licensed ambrisentan from Myogen for all territories outside of the United States, where Myogen retains exclusive rights. Myogen also conducts a target and drug discovery research program focused on the development of disease-modifying drugs for the treatment of chronic heart failure and related cardiovascular disorders. Please visit Myogen's website at www.myogen.com. Investor Relations Contact Info: Derek Cole Director, Investor Relations Myogen, Inc. 7575 W. 103rd Avenue, Suite 102 Westminster, CO 80021-5426 Tel: 303-410-6666 Fax: 303-410-6667 IR@myogen.com Company Contact Info: 7575 West 103rd Avenue Suite 102 Westminster, CO 80021 Phone: 303-410-6666 Fax: 303-410-6667 Exchange: Nasdaq Source: Company website Last Updated: 04/14/2006